Β-arrestin: a Signaling Molecule and Potential Therapeutic Target for Heart Failure

Overview

Journal J Mol Cell Cardiol

Specialty Cardiology & Vascular Diseases

Date 2010 Nov 16

PMID 21074538

Citations 40

Authors

Nabila Noor

Chetan B Patel

Howard A Rockman

Affiliations

Soon will be listed here.

Abstract

Currently, some of the most effective treatments for heart failure target GPCRs such as the beta-adrenergic receptors (β1AR and β2AR) and angiotensin II type IA receptors (AT1aR). Ligands for these receptors not only function by blocking the deleterious G-protein mediated pathway leading to heart failure, but also signal via G-protein independent pathways that involve receptor phosphorylation by G-protein receptor kinases (GRKs) leading to recruitment of the multifunctional protein, β-arrestin. Originally thought to play a role in GPCR desensitization and internalization, β-arrestin has recently been shown to mediate signaling independent of classical second messengers in a way that is often protective to the heart. The multi-functionality of β-arrestin makes it an intriguing molecule in the development of the next generation of drugs for cardiac diseases with the potential to simultaneously inhibit deleterious G-protein dependent pathways while activating beneficial β-arrestin mediated signaling. In this review, we explore various facets of β-arrestin signaling and offer a perspective on its potential role as a key signaling molecule in the treatment of heart failure. This article is part of a special issue entitled "Key Signaling Molecules in Hypertrophy and Heart Failure."

Citing Articles

Decoding the κ Opioid Receptor (KOR): Advancements in Structural Understanding and Implications for Opioid Analgesic Development.

Li Z, Huang R, Xia M, Chang N, Guo W, Liu J Molecules. 2024; 29(11).

PMID: 38893511 PMC: 11173883. DOI: 10.3390/molecules29112635.

Adaptor molecules mediate negative regulation of macrophage inflammatory pathways: a closer look.

Baig M, Barmpoutsi S, Bharti S, Weigert A, Hirani N, Atre R Front Immunol. 2024; 15:1355012.

PMID: 38482001 PMC: 10933033. DOI: 10.3389/fimmu.2024.1355012.

Three-Dimensional Structural Insights Have Revealed the Distinct Binding Interactions of Agonists, Partial Agonists, and Antagonists with the µ Opioid Receptor.

Li Z, Liu J, Dong F, Chang N, Huang R, Xia M Int J Mol Sci. 2023; 24(8).

PMID: 37108204 PMC: 10138646. DOI: 10.3390/ijms24087042.

Atypical Roles of the Chemokine Receptor ACKR3/CXCR7 in Platelet Pathophysiology.

Chatterjee M Cells. 2022; 11(2).

PMID: 35053329 PMC: 8773869. DOI: 10.3390/cells11020213.

Cell therapy rescues aging-induced beta-1 adrenergic receptor and GRK2 dysfunction in the coronary microcirculation.

Rowe G, Tracy E, Beare J, LeBlanc A Geroscience. 2021; 44(1):329-348.

PMID: 34608562 PMC: 8811091. DOI: 10.1007/s11357-021-00455-6.

References

Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C . EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature. 2000; 402(6764):884-8. DOI: 10.1038/47260. View

Wilden U, Hall S, Kuhn H . Phosphodiesterase activation by photoexcited rhodopsin is quenched when rhodopsin is phosphorylated and binds the intrinsic 48-kDa protein of rod outer segments. Proc Natl Acad Sci U S A. 1986; 83(5):1174-8. PMC: 323037. DOI: 10.1073/pnas.83.5.1174. View

Couchonnal L, Anderson M . The role of calmodulin kinase II in myocardial physiology and disease. Physiology (Bethesda). 2008; 23:151-9. DOI: 10.1152/physiol.00043.2007. View

Daub H, Weiss F, Wallasch C, Ullrich A . Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature. 1996; 379(6565):557-60. DOI: 10.1038/379557a0. View

Allan L, Morrice N, Brady S, Magee G, Pathak S, Clarke P . Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK. Nat Cell Biol. 2003; 5(7):647-54. DOI: 10.1038/ncb1005. View

DeWire S, Ahn S, Lefkowitz R, Shenoy S . Beta-arrestins and cell signaling. Annu Rev Physiol. 2007; 69:483-510. DOI: 10.1146/annurev.physiol.69.022405.154749. View

Aplin M, Christensen G, Schneider M, Heydorn A, Gammeltoft S, Kjolbye A . The angiotensin type 1 receptor activates extracellular signal-regulated kinases 1 and 2 by G protein-dependent and -independent pathways in cardiac myocytes and langendorff-perfused hearts. Basic Clin Pharmacol Toxicol. 2007; 100(5):289-95. DOI: 10.1111/j.1742-7843.2007.00063.x. View

Gaidarov I, Krupnick J, Falck J, Benovic J, Keen J . Arrestin function in G protein-coupled receptor endocytosis requires phosphoinositide binding. EMBO J. 1999; 18(4):871-81. PMC: 1171180. DOI: 10.1093/emboj/18.4.871. View

Luttrell L, Ferguson S, Daaka Y, Miller W, Maudsley S, Della Rocca G . Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science. 1999; 283(5402):655-61. DOI: 10.1126/science.283.5402.655. View

10.

Perry S, Baillie G, Kohout T, McPhee I, Magiera M, Ang K . Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins. Science. 2002; 298(5594):834-6. DOI: 10.1126/science.1074683. View

11.

Molkentin J, Dorn 2nd G . Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol. 2001; 63:391-426. DOI: 10.1146/annurev.physiol.63.1.391. View

12.

Ghanouni P, Gryczynski Z, Steenhuis J, Lee T, Farrens D, Lakowicz J . Functionally different agonists induce distinct conformations in the G protein coupling domain of the beta 2 adrenergic receptor. J Biol Chem. 2001; 276(27):24433-6. DOI: 10.1074/jbc.C100162200. View

13.

Waskiewicz A, Flynn A, Proud C, Cooper J . Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J. 1997; 16(8):1909-20. PMC: 1169794. DOI: 10.1093/emboj/16.8.1909. View

14.

Wu N, Hanson S, Francis D, Vishnivetskiy S, Thibonnier M, Klug C . Arrestin binding to calmodulin: a direct interaction between two ubiquitous signaling proteins. J Mol Biol. 2006; 364(5):955-63. PMC: 1783800. DOI: 10.1016/j.jmb.2006.09.075. View

15.

Shenoy S, Drake M, Nelson C, Houtz D, Xiao K, Madabushi S . beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor. J Biol Chem. 2005; 281(2):1261-73. DOI: 10.1074/jbc.M506576200. View

16.

Naga Prasad S, Laporte S, Chamberlain D, Caron M, Barak L, Rockman H . Phosphoinositide 3-kinase regulates beta2-adrenergic receptor endocytosis by AP-2 recruitment to the receptor/beta-arrestin complex. J Cell Biol. 2002; 158(3):563-75. PMC: 2173831. DOI: 10.1083/jcb.200202113. View

17.

Lanfear D, Jones P, Marsh S, Cresci S, McLeod H, Spertus J . Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA. 2005; 294(12):1526-33. DOI: 10.1001/jama.294.12.1526. View

18.

Brodde O, Michel M . Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev. 1999; 51(4):651-90. View

19.

Korshunov V, Berk B . Smooth muscle apoptosis and vascular remodeling. Curr Opin Hematol. 2008; 15(3):250-4. DOI: 10.1097/MOH.0b013e3282f97d71. View

20.

Moore C, Milano S, Benovic J . Regulation of receptor trafficking by GRKs and arrestins. Annu Rev Physiol. 2006; 69:451-82. DOI: 10.1146/annurev.physiol.69.022405.154712. View